The United States has lifted tariffs on pharmaceutical products from the UK.

The U.S. has agreed to eliminate Section 232 tariffs on pharmaceutical products from the U.K., as stated in a White House press release. This deal encompasses U.K.-based pharmaceuticals and medical technology, with the U.K. committing to increase its National Health Service spending on medicines by 25%. In exchange, the U.S. will refrain from investigating U.K. pricing practices under Section 301 during President Trump's term. This agreement is part of the broader U.S.-U.K. Economic Prosperity Deal aimed at reducing tariffs and enhancing market access.